Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors associated with the number of drugs in darunavir/cobicistat regimens.
Martinez E, Negredo E, Knobel H, Ocampo A, Sanz J, Garcia-Fraile L, Martin-Carbonero L, Lozano F, Gonzalez-Domenech CM, Gutierrez M, Montero M, Boix V, Payeras A, Torralba M, Gonzalez-Cordon A, Moreno A, Alejos B, Perez-Elias MJ; GeSIDA 9316 CODAR Study Group. Martinez E, et al. J Antimicrob Chemother. 2020 Jan 1;75(1):208-214. doi: 10.1093/jac/dkz399. J Antimicrob Chemother. 2020. PMID: 31586414
Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance.
De Miguel Buckley R, Rial-Crestelo D, Montejano R, Pinto A, Jimenez-Gonzalez M, Lagarde M, Esteban-Cantos A, Aranguren-Rivas P, Cadiñanos J, Bisbal O, Castro JM, Santacreu-Guerrero M, Bermejo-Plaza L, Moreno V, Hernando A, Martín-Carbonero L, Rubio R, Delgado R, Arribas JR, Pulido F; Antiretroviral Treatment Guided by Proviral Genotype (ART-PRO) Study Group. De Miguel Buckley R, et al. Open Forum Infect Dis. 2022 Nov 8;9(11):ofac610. doi: 10.1093/ofid/ofac610. eCollection 2022 Nov. Open Forum Infect Dis. 2022. PMID: 36447613 Free PMC article.
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
Barrios A, Rendón A, Negredo E, Barreiro P, Garcia-Benayas T, Labarga P, Santos J, Domingo P, Sánchez-Conde M, Maida I, Martín-Carbonero L, Núñez M, Blanco F, Clotet B, Sambeat MA, Gil P, Gonzalez-Lahoz J, Cooper D, Soriano V. Barrios A, et al. AIDS. 2005 Mar 24;19(6):569-75. doi: 10.1097/01.aids.0000163933.14649.93. AIDS. 2005. PMID: 15802975 Clinical Trial.
Severe liver disease associated with prolonged exposure to antiretroviral drugs.
Maida I, Núñez M, Ríos MJ, Martín-Carbonero L, Sotgiu G, Toro C, Rivas P, Barreiro P, Mura MS, Babudieri S, Garcia-Samaniego J, González-Lahoz J, Soriano V. Maida I, et al. J Acquir Immune Defic Syndr. 2006 Jun;42(2):177-82. doi: 10.1097/01.qai.0000221683.44940.62. J Acquir Immune Defic Syndr. 2006. PMID: 16688096
Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients.
Núñez M, Mariño A, Miralles C, Berdún MA, Sola J, Hernandez-Burruezo JJ, Galindo MJ, Barreiro P, Martin-Carbonero L, Soriano V. Núñez M, et al. J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):439-44. doi: 10.1097/QAI.0b013e318061b5d9. J Acquir Immune Defic Syndr. 2007. PMID: 17468669 Clinical Trial.
Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
Soriano V, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de los Santos I, San Joaquín I, Echeverria S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola J, Blanco F, Martin-Carbonero L, García-Samaniego J, Nuñez M; PRESCO Study Group. Soriano V, et al. Antivir Ther. 2007;12(4):469-76. Antivir Ther. 2007. PMID: 17668555 Clinical Trial.
186 results